GDC-0623 (RG 7421) is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

Ginsenoside Rg1 (Panaxoside Rg1) is a class of steroid glycosides, and triterpene saponins found exclusively in the plant genus Panax (ginseng). It improves spatial learning and increase hippocampal synaptophysin level in mice, plus demonstrates estrogen-like activity.

GDC-0425 (RG-7602) is an orally administered, selective small molecule inhibitor targeting checkpoint kinase 1 (ChK1), utilized in research focused on various malignancies [1] [2].

GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.

Alectinib (RG-7853) is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.

RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).

Tyrphostin 23 (AG18) inhibits EGFR with IC50 of 35 μM.

RG14620 (Tyrphostin RG14620) is an epidermal growth factor receptor (EGFR) inhibitor.

Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).

Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting Her3 (ErbB3) [1].

Galegenimab (FHTR 2163; RG 6147; RO 7171009), an antibody fragment targeting High-temperature requirement A1 (HTRA1), is utilized in the research of age-related macular degeneration (AMD) [1].

Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).

Lampalizumab (RG 7417), a humanized monoclonal antibody, selectively inhibits complement Factor D in the alternative complement pathway by binding to an exosite and sterically hindering Factor B's access to the active site. It is employed in the study of age-related macular degeneration (AMD) [1] [2].

Crenezumab (MABT 5102A; RG 7412), a fully humanized monoclonal antibody targeting Aβ, exhibits binding affinity for various forms of Aβ, including soluble, oligomeric, and fibrillar. It is utilized in the study of Alzheimer's disease [1].

Sekikaic acid is a phenolic lichen metabolite that has been found in H. obscurata and has diverse biological activities. It scavenges superoxide and DPPH radicals in cell-free assays when used at a concentration of 0.5 µM. Sekikaic acid is active against the rg recombinant strain of respiratory syncytial virus (RSV; IC50 = 5.69 µg/ml). It inhibits the protein-protein interaction between mixed lineage leukemia 1 (MLL1) and the GACKIX domain of CREB-binding protein (CBP; IC50 = 34 µM).

Semorinemab (RG 6100), an anti-Tau humanized IgG4 monoclonal antibody, selectively targets the N-terminal portion of the Tau protein, specifically amino acid residues 6-23. It exhibits a binding affinity to human Tau with a dissociation constant (Kd) of 3.8 nM. This compound is utilized in Alzheimer's Disease research [1].

(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].

lavendustin A (RG-14355) is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.

Afasevikumab (RG 7624; RO 5553110; NI-1401), a fully human monoclonal IgG1κ antibody, neutralizes both IL-17A and IL-17F, exhibiting anti-inflammatory activities [1].

Imgatuzumab (RG 7160), a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), serves as an immunomodulator. It is utilized in cancer research [1].

β-Amyloid peptide(16-20), with the amino acid sequence (KLVFF) derived from Amyloid-β (Abeta), functions as an efficient inhibitor of Abeta fibril formation. This compound is modified with RG-/-GR-NH2 residues at both its N- and C-terminal ends to enhance solubility [1].